Birth Size and Gestational Age Specific Outcomes of Inhaled Nitric Oxide Therapy in Preterm Neonates with Clinically Diagnosed Pulmonary Hypertension

Abstract

Objective Among neonates of 22 to 29 weeks' gestational age (GA) who required mechanical ventilation for the treatment of respiratory distress syndrome (RDS) and clinically diagnosed pulmonary hypertension (PH), we tested our hypothesis that the association between early treatment with inhaled nitric oxide (iNO) and survival would vary according to birth size and GA.

Study Design Because iNO was not randomly prescribed to patients in this cohort, we used propensity score matching to pair a neonate who received iNO at a chronological age of ≤7 days with an unexposed neonate with similar baseline characteristics. The primary outcome was inhospital mortality, which we evaluated based on size for GA and GA strata using the Cox proportional hazards regression model.

Results Among 1,531 neonates who met study criteria, we created a propensity score matched cohort of 615 pairs of neonates (iNO-exposed and unexposed). The risk of inhospital mortality for iNO-exposed neonates was observed only in the minority (<10%) who were large for GA, though this finding did not persist when matching for illness severity.

Conclusion Early treatment with iNO is not associated with survival in most extremely premature neonates with RDS and clinically diagnosed PH when stratified for birth size or GA.

Keywords

inhaled nitric oxide - neonate - prematurity - pulmonary hypertension - respiratory distress syndrome

• References

• 1 Fanaroff AA, Stoll BJ, Wright LL. , et al; NICHD Neonatal Research Network. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007; 196 (02) 147.e1-147.e8
• 2 Stoll BJ, Hansen NI, Bell EF. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 2015; 314 (10) 1039-1051
• 3 Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 2008; 371 (9608): 261-269
• 4 Mourani PM, Sontag MK, Younoszai A. , et al. Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med 2015; 191 (01) 87-95
• 5 Mirza H, Ziegler J, Ford S, Padbury J, Tucker R, Laptook A. Pulmonary hypertension in preterm infants: prevalence and association with bronchopulmonary dysplasia. J Pediatr 2014; 165 (05) 909-914
• 6 Berenz A, Vergales JE, Swanson JR, Sinkin RA. Evidence of early pulmonary hypertension is associated with increased mortality in very low birth weight infants. Am J Perinatol 2017; 34 (08) 801-807
• 7 Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2001; (04) CD000399
• 8 Ellsworth MA, Harris MN, Carey WA, Spitzer AR, Clark RH. Off-label use of inhaled nitric oxide after release of NIH consensus statement. Pediatrics 2015; 135 (04) 643-648
• 9 Handley SC, Steinhorn RH, Hopper AO. , et al. Inhaled nitric oxide use in preterm infants in California neonatal intensive care units. J Perinatol 2016; 36 (08) 635-639
• 10 Subhedar NV, Shaw NJ. Changes in oxygenation and pulmonary haemodynamics in preterm infants treated with inhaled nitric oxide. Arch Dis Child Fetal Neonatal Ed 1997; 77 (03) F191-F197
• 11 Kinsella JP, Walsh WF, Bose CL. , et al. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet 1999; 354 (9184): 1061-1065
• 12 Srisuparp P, Heitschmidt M, Schreiber MD. Inhaled nitric oxide therapy in premature infants with mild to moderate respiratory distress syndrome. J Med Assoc Thai 2002; 85 (Suppl. 02) S469-S478
• 13 Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003; 349 (22) 2099-2107
• 14 Field D, Elbourne D, Truesdale A. , et al; INNOVO Trial Collaborating Group. Neonatal ventilation with inhaled nitric oxide versus ventilatory support without inhaled nitric oxide for preterm infants with severe respiratory failure: the INNOVO multicentre randomised controlled trial (ISRCTN 17821339). Pediatrics 2005; 115 (04) 926-936
• 15 Van Meurs KP, Wright LL, Ehrenkranz RA. , et al; Preemie Inhaled Nitric Oxide Study. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 2005; 353 (01) 13-22
• 16 Van Meurs KP, Hintz SR, Ehrenkranz RA. , et al. Inhaled nitric oxide in infants >1500 g and <34 weeks gestation with severe respiratory failure. J Perinatol 2007; 27 (06) 347-352
• 17 Hascoet JM, Fresson J, Claris O. , et al. The safety and efficacy of nitric oxide therapy in premature infants. J Pediatr 2005; 146 (03) 318-323
• 18 Dani C, Bertini G, Pezzati M, Filippi L, Cecchi A, Rubaltelli FF. Inhaled nitric oxide in very preterm infants with severe respiratory distress syndrome. Acta Paediatr 2006; 95 (09) 1116-1123
• 19 Kinsella JP, Cutter GR, Walsh WF. , et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 2006; 355 (04) 354-364
• 20 Ballard RA, Truog WE, Cnaan A. , et al; NO CLD Study Group. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006; 355 (04) 343-353
• 21 Mercier JC, Hummler H, Durrmeyer X. , et al; EUNO Study Group. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. Lancet 2010; 376 (9738): 346-354
• 22 The Franco-Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet 1999; 354 (9184): 1066-1071
• 23 Barrington KJ, Finer N. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2010; (12) CD000509
• 24 Donohue PK, Gilmore MM, Cristofalo E. , et al. Inhaled nitric oxide in preterm infants: a systematic review. Pediatrics 2011; 127 (02) e414-e422
• 25 Barrington KJ, Finer N, Pennaforte T. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2017; 1: CD000509
• 26 Askie LM, Ballard RA, Cutter GR. , et al; Meta-analysis of Preterm Patients on Inhaled Nitric Oxide Collaboration. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. Pediatrics 2011; 128 (04) 729-739
• 27 Hasan SU, Potenziano J, Konduri GG. , et al; Newborns Treated With Nitric Oxide (NEWNO) Trial Group. Effect of inhaled nitric oxide on survival without bronchopulmonary dysplasia in preterm infants: a randomized clinical trial. JAMA Pediatr 2017; 171 (11) 1081-1089
• 28 Wei QF, Pan XN, Li Y. , et al. Efficacy of inhaled nitric oxide in premature infants with hypoxic respiratory failure. Zhongguo Dang Dai Er Ke Za Zhi 2014; 16 (08) 805-809
• 29 Su PH, Chen JY. Inhaled nitric oxide in the management of preterm infants with severe respiratory failure. J Perinatol 2008; 28 (02) 112-116
• 30 Skimming JW, DeMarco VG, Cassin S. The effects of nitric oxide inhalation on the pulmonary circulation of preterm lambs. Pediatr Res 1995; 37 (01) 35-40
• 31 Kumar VH, Hutchison AA, Lakshminrusimha S, Morin III FC, Wynn RJ, Ryan RM. Characteristics of pulmonary hypertension in preterm neonates. J Perinatol 2007; 27 (04) 214-219
• 32 Abman SH, Kinsella JP, Schaffer MS, Wilkening RB. Inhaled nitric oxide in the management of a premature newborn with severe respiratory distress and pulmonary hypertension. Pediatrics 1993; 92 (04) 606-609
• 33 Chock VY, Van Meurs KP, Hintz SR. , et al; NICHD Neonatal Research Network. Inhaled nitric oxide for preterm premature rupture of membranes, oligohydramnios, and pulmonary hypoplasia. Am J Perinatol 2009; 26 (04) 317-322
• 34 Carey WA, Weaver AL, Mara KC, Clark RH. Inhaled nitric oxide in extremely premature neonates with respiratory distress syndrome. Pediatrics 2018; 141 (03) e20173108
• 35 Chandrasekharan P, Kozielski R, Kumar VH. , et al. Early use of inhaled nitric oxide in preterm infants: is there a rationale for selective approach?. Am J Perinatol 2017; 34 (05) 428-440
• 36 Abman SH, Hansmann G, Archer SL. , et al; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; and the American Thoracic Society. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation 2015; 132 (21) 2037-2099
• 37 Kinsella JP, Steinhorn RH, Krishnan US. , et al. Recommendations for the use of inhaled nitric oxide therapy in premature newborns with severe pulmonary hypertension. J Pediatr 2016; 170: 312-314
• 38 Spitzer AR, Ellsbury DL, Handler D, Clark RH. The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system--tools for “meaningful use” in continuous quality improvement. Clin Perinatol 2010; 37 (01) 49-70
• 39 Tolia VN, Patrick SW, Bennett MM. , et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med 2015; 372 (22) 2118-2126
• 40 Raju TN, Higgins RD, Stark AR, Leveno KJ. Optimizing care and outcome for late-preterm (near-term) infants: a summary of the workshop sponsored by the National Institute of Child Health and Human Development. Pediatrics 2006; 118 (03) 1207-1214
• 41 Laughon MM, Avant D, Tripathi N. , et al. Drug labeling and exposure in neonates. JAMA Pediatr 2014; 168 (02) 130-136
• 42 Autmizguine J, Hornik CP, Benjamin Jr DK. , et al; Best Pharmaceuticals for Children Act—Pediatric Trials Network Administrative Core Committee. Anaerobic antimicrobial therapy after necrotizing enterocolitis in VLBW infants. Pediatrics 2015; 135 (01) e117-e125
• 43 Trembath A, Hornik CP, Clark R, Smith PB, Daniels J, Laughon M. ; Best Pharmaceuticals for Children Act—Pediatric Trials Network. Comparative effectiveness of surfactant preparations in premature infants. J Pediatr 2013; 163 (04) 955-960
• 44 Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS. New intrauterine growth curves based on United States data. Pediatrics 2010; 125 (02) e214-e224
• 45 Aliaga S, Clark RH, Laughon M. , et al. Changes in the incidence of candidiasis in neonatal intensive care units. Pediatrics 2014; 133 (02) 236-242
• 46 Ellsworth KR, Ellsworth MA, Weaver AL, Mara KC, Clark RH, Carey WA. Association of early inhaled nitric oxide with the survival of preterm neonates with pulmonary hypoplasia. JAMA Pediatr 2018; 172 (07) e180761
• 47 Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006; 117 (06) 1979-1987
• 48 Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics 2006; 117 (01) 67-74
• 49 Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70 (01) 41-55
• 50 D'Agostino Jr RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17 (19) 2265-2281
• 51 Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28 (25) 3083-3107
• 52 Clark RH, Ursprung RL, Walker MW, Ellsbury DL, Spitzer AR. The changing pattern of inhaled nitric oxide use in the neonatal intensive care unit. J Perinatol 2010; 30 (12) 800-804
• 53 Rabinovitch M. Pulmonary hypertension: pathophysiology as a basis for clinical decision making. J Heart Lung Transplant 1999; 18 (11) 1041-1053
• 54 Baker CD, Abman SH, Mourani PM. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Pediatr Allergy Immunol Pulmonol 2014; 27 (01) 8-16
• 55 Mirza H, Ziegler J, Ford S, Padbury J, Tucker R, Laptook A. Temporal profile of early pulmonary hypertension in preterm infants. Am J Perinatol 2016; 33 (09) 903-909
• 56 Toyono M, Harada K, Takahashi Y, Takada G. Maturational changes in left ventricular contractile state. Int J Cardiol 1998; 64 (03) 247-252
• 57 Igarashi H, Shiraishi H, Endoh H, Yanagisawa M. Left ventricular contractile state in preterm infants: relation between wall stress and velocity of circumferential fiber shortening. Am Heart J 1994; 127 (05) 1336-1340
• 58 Simonneau G, Gatzoulis MA, Adatia I. , et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (25, Suppl): D34-D41
• 59 Friedman WF. The intrinsic physiologic properties of the developing heart. Prog Cardiovasc Dis 1972; 15 (01) 87-111
• 60 Rudolph AM. Myocardial growth before and after birth: clinical implications. Acta Paediatr 2000; 89 (02) 129-133
• 61 Page E, Buecker JL. Development of dyadic junctional complexes between sarcoplasmic reticulum and plasmalemma in rabbit left ventricular myocardial cells. Morphometric analysis. Circ Res 1981; 48 (04) 519-522
• 62 Giesinger RE, More K, Odame J, Jain A, Jankov RP, McNamara PJ. Controversies in the identification and management of acute pulmonary hypertension in preterm neonates. Pediatr Res 2017; 82 (06) 901-914
• 63 Finer NN, Evans N. Inhaled nitric oxide for the preterm infant: evidence versus practice. Pediatrics 2015; 135 (04) 754-756
• 64 de Waal K, Kluckow M. Prolonged rupture of membranes and pulmonary hypoplasia in very preterm infants: pathophysiology and guided treatment. J Pediatr 2015; 166 (05) 1113-1120
• 65 Desandes R, Desandes E, Droullé P, Didier F, Longrois D, Hascoët JM. Inhaled nitric oxide improves oxygenation in very premature infants with low pulmonary blood flow. Acta Paediatr 2004; 93 (01) 66-69
• 66 Evans N. Towards rational use of inhaled nitric oxide in preterm babies. Acta Paediatr 2016; 105 (02) 121-122
• 67 Su BH, Lin HY, Huang FK, Tsai ML, Huang YT. Circulatory management focusing on preventing intraventricular hemorrhage and pulmonary hemorrhage in preterm infants. Pediatr Neonatol 2016; 57 (06) 453-462
• 68 Subhedar NV, Ryan SW, Shaw NJ. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Arch Dis Child Fetal Neonatal Ed 1997; 77 (03) F185-F190
• 69 Boghossian NS, Geraci M, Edwards EM, Horbar JD. In-hospital outcomes in large for gestational age infants at 22-29 weeks of gestation. J Pediatr 2018; 198: 174-180
• 70 Boghossian NS, Geraci M, Edwards EM, Horbar JD. Morbidity and mortality in small for gestational age infants at 22 to 29 weeks' gestation. Pediatrics 2018; 141 (02) e20172533
• 71 De Jesus LC, Pappas A, Shankaran S. , et al; Eunice Kennedy Shriver National Institute of Health and Human Development Neonatal Research Network. Outcomes of small for gestational age infants born at <27 weeks' gestation. J Pediatr 2013; 163 (01) 55-60.e1 , 3
• 72 Ambalavanan N, Van Meurs KP, Perritt R. , et al; NICHD Neonatal Research Network, Bethesda, MD. Predictors of death or bronchopulmonary dysplasia in preterm infants with respiratory failure. J Perinatol 2008; 28 (06) 420-426
• 73 Garite TJ, Clark R, Thorp JA. Intrauterine growth restriction increases morbidity and mortality among premature neonates. Am J Obstet Gynecol 2004; 191 (02) 481-487
• 74 Kc A, Wrammert J, Nelin V, Ewald U, Clark R, Målqvist M. Level of mortality risk for babies born preterm or with a small weight for gestation in a tertiary hospital of Nepal. BMC Public Health 2015; 15: 877
• 75 Collura CA, Mara KC, Weaver AL, Clark RH, Carey WA. Outcomes of early inhaled nitric oxide use in premature African American neonates. J Perinatol 2018; 38 (12) 1657-1665